BEACON CAPITAL HOLDINGS

"TENACITAS VINCIT OMNIA"

7

Partners

1.5B

Capital

39

Deals

5.4x

Returns

Characteristic of Past Deals:

Portfolio Diversification In Life Science Strategy

-Total number of companies advisory and or investment: 48

-Top 6 companies invested in accounted for $900 million of capital deployed, some 56% of the total investment portfolio or a 5 year period

-Remaining 42 companies averaged some $21 million each

Nationality:

US companies comprised 70% of the portfolio by investment amount; 60% by number

15 non-US companies from 12 different countries: Israel, Netherlands, UK, Ireland, China, Caiman Island, Brazil, Canada, Mexico, Spain, Italy.    Investment returns were similar across nationalities.

Underlying Asset Scientific Breakdown:

-Therapeutics comprised some 85% by volume of investment, with medical device companies the remainder.  There were a total of 30 lead research areas/indications across the companies advised and invested in. 

 

R&D/Indications:

Oncology

CNS

Immunology

Gene Therapy

Aging

Regenerative

MedTech devices

Organ Implantation/Transplantation

Recent News

© 2009 by Beacon Capital